Cybin’s Sublingual Psilocybin Strips Head to Clinical Trials for Dose-Finding
The first trial will determine the sublingual dose equivalent to 25 mg psilocybin administered orally.
Mental Health - Page 10
MindMed and Liechti Lab to Conduct the First Clinical Trial Combining LSD and MDMA
Researchers will examine whether MDMA can offset some of the negative side effects of LSD in a therapeutic setting.
The Mechanisms of Change in Psychedelic Assisted Psychotherapy
A new study sheds light on cognitive behavioral change mechanisms underlying psychedelic assisted psychotherapy.
The Role of the Claustrum in the Psychedelic Experience
Brain scans show that psilocybin modulates claustrum connectivity in brain networks.
Beneficial Synergy: Teaming Psilocybin with Mindfulness Meditation
A double-blind study reveals that mindfulness meditation practice may amplify the positive effects of psilocybin while reducing the likelihood of a bad trip.
Examining the Cognitive Neuroscience of Psychedelics
The new REBUS model helps explain the subjective and neurochemical effects of psychedelics on the brain.
Psychedelic Assisted Psychotherapy and Experiential Efficacy
With the paradigm shift created by psychedelics, a recent study suggests reconsidering the medical model of mental illness.
The Growing Evidence for Psilocybin-Facilitated Smoking Cessation
Comments from Matthew Johnson of Johns Hopkins provide an update on this research.
Psilocybin to Treat Anxiety and Depression in Cancer Patients
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.
Beyond Ayahuasca: Therapeutic Effects of N,N-Dimethyltryptamine (DMT)
Researchers are uncovering reasons to think there’s more to DMT than just hallucinations.